See All Slides - tctmd.com

Slides

Presentation TCT 2012

What Is FFR, and How Is It Different from Other Indices?

Presenter: William Fearon

October 25, 2012

Presentation TCT 2012

Session and Participant Introduction

Presenter: Anthony Gershlick

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

Optimizing Adjunct Pharmacotherapy Before, During, and After PCI: An Evidence-Based Tutorial

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

Presenter: Nicolo Piazza

October 25, 2012

Presentation TCT 2012

Case 3: FFR and Left Main Disease

Presenter: Michalis Hamilos

October 25, 2012

Presentation TCT 2012

Topic Essentials(2)

Presenter: Theodore Schreiber

October 25, 2012

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

Presentation TCT 2012

Statement: Second Generation DES Are Safer Than BMS and Should Be Used in All Patients

Presenter: Marco Valgimigli

October 25, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

Advertisement

Slides

What Is FFR, and How Is It Different from Other Indices?

Session and Participant Introduction

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Optimizing Adjunct Pharmacotherapy Before, During, and After PCI: An Evidence-Based Tutorial

The European TAVR “Test Track”: After 5 Years, Have TAVR Use Patterns Drifted Out of Control?

Case 3: FFR and Left Main Disease

Topic Essentials(2)

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Statement: Second Generation DES Are Safer Than BMS and Should Be Used in All Patients

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content